|
News For JNJ;PFE;BIIB;AMGN From The Last 14 Days Check below for free stories on JNJ;PFE;BIIB;AMGN the last two weeks. |
|
|
| May 17, 2013 |
| 06:19 EDT |  | JNJ | J&J to end sales of of metal-on-metal hip replacements, Bloomberg reports
 Subscribe for More Information |
|
| May 16, 2013 |
| 08:55 EDT |  | PFE | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| 07:29 EDT | | BIIB | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. |
|
| May 15, 2013 |
| 16:51 EDT |  | JNJ | FDA approves Simponi to treat ulcerative colitis
Subscribe for More Information |
|
| May 14, 2013 |
| 15:09 EDT | | BIIB | Biogen has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov host a conference call with CEO George Scangos and CFO Paul Clancy on May 17 at 10 am. |
|
| May 13, 2013 |
| 11:12 EDT |  | BIIB | Biogen MS drug scripts grew 38% week-over-week, says Leerink
Subscribe for More Information |
|
| 08:55 EDT | | AMGN | Biosimiliar drug bill to be taken up in Senate, LA Times reports
Subscribe for More Information |
|
| 07:34 EDT | | BIIB | Biogen says FDA accepts BLA for Eloctate
Subscribe for More Information |
|
| May 10, 2013 |
| 16:29 EDT |  | PFE | On The Fly: Closing Wrap
Subscribe for More Information |
|
| 12:31 EDT | | PFE | On The Fly: Midday Wrap
Subscribe for More Information |
| |
| 11:48 EDT | | JNJ, PFE | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| 09:21 EDT | | PFE | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 08:08 EDT | | PFE | Pain Therapeutics discloses Pfizer reassessing continued Remoxy partnership
Pain Therapeutics (PTIE) disclosed a letter its CEO was sent from partner Pfizer (PFE) in which the drug maker said it is reassessing its endorsement of the Remoxy program "given the years of delay, additional cost incurred to bring the program to this point and development work left in the program." Pfizer said it will be reaching out to Pain Therapeutics "shortly" to have a confidential discussion about the terms of the companies' contractual agreement over the pain drug. Pfizer that it appears there is a regulatory pathway forward for Remoxy, but that the company does not expect to respond to submit a Complete Response letter for Remoxy to the FDA before mid-2015. Pfizer added in its letter to Pain Therapeutics "no final decision has been made at this time" on how it will proceed with the Remoxy development program. Shares of Pain Therapeutics fell 47% to $2.81 in pre-market trading following the disclosure of the correspondence. |
|
| 08:00 EDT | | BIIB | Biogen should be bought on weakness before Q2 Tecfidera data, says Stifel
Stifel recommends buying Biogen on any weakness before the company reports Q2 Tecfidera sales data. The firm thinks that any continued strength in Tecfidera prescription data will cause analysts to revise their estimates higher, and it keeps a Buy rating on the shares. |
|
| 07:46 EDT | | PFE | DURECT says additional clinical studies needed for Remoxy
DURECT (DRRX) announced that Pfizer (PFE) has provided an update on Remoxy in a regulatory filing. Pfizer's disclosure included: "We have been working to address the issues raised in the letter, which primarily relate to manufacturing. We met with the FDA in March 2013 to discuss our plan to address the June 2011 "complete response" letter. We received written guidance from the FDA in May regarding required next steps, including additional clinical studies, to address the letter. Based on this guidance, we are considering our options with respect to Remoxy. If we elect to continue development of Remoxy, we would not expect to submit a response to the 'complete response' letter before mid-2015." DURECT said it understands from Pfizer that additional clinical studies are necessary and include, in part, a pivotal bioequivalence study with the modified formulation to bridge to the clinical data conducted with the original formulation, as well as an abuse potential study with the modified Remoxy formulation. Remoxy is based on DURECT's ORADUR technology. Shares of Pfizer's Remoxy partner Pain Therapeutics (PTIE) are down 56% in pre-market trading, while shares of DURECT are down 13%, or 20c, to $1.39. |
|
| 06:16 EDT | | JNJ | Obesity surgery booming in India, Bloomberg reports
Subscribe for More Information |
|
| May 9, 2013 |
| 17:09 EDT | | JNJ | Johnson & Johnson deal to settle sales practices probe stalls, WSJ reports
Johnson & Johnson's $2.2B settlement with the Justice Department related to its promotion of certain drugs is on hold as the company is looking to avoid language in the agreement that could make it vulnerable to private lawsuits, reports The Wall Street Journal, citing people familiar with the talks. Reference Link |
|
| 16:59 EDT | | BIIB | Isis Pharmaceuticals earns $3.5M from Biogen
Subscribe for More Information |
|
| 16:48 EDT | | AMGN | Amgen, Zhejiang Beta Pharma announce joint venture in China
Subscribe for More Information |
|
| 10:17 EDT | | PFE | Shire trades higher in London amid takeover chatter, Guardian says
Subscribe for More Information |
| |
|
|
|
|
